• Transition of CEO role

    Posted on 15 May 2013

    The Board of Photonz Corporation is delighted to announce the appointment of Dr James Campbell to the role of CEO as part of a staged transition that sees Dr Greg Collier assume the CEO role of the ASX-listed biotech company Invion Limited. 

  • Photonz's Chief Scientific Officer Wins NZBIO Award

    Posted on 20 March 2013

    Dr Hywel Griffiths, Chief Scientific Officer for Photonz Corp. was named the 2013 Young Biotechnologist of the Year by NZBIO at an award ceremony Tuesday evening.


  • Seeking commercial partners

    Posted on 9 November 2012

    AUCKLAND via ALGAE WORLD ASIA CONFERENCE SINGAPORE – 8 November 2012 – Talks are underway involving potential partners of Photonz Corporation as the company is finalising its process for manufacturing eicosapentaenoic acid (EPA) by fermentation of micro-algae.


Photonz shifts gears from up-scaling manufacture to seeking commercial partners

Posted on 9 November 2012

Photonz chief executive Dr Greg Collier is meeting with interested parties at the 5th Algae World Asia conference (7 - 9 November) which has brought together representatives of industry and investor groups from across the region.

“The years that we have put into developing this product, gaining IP control and up-scaling the manufacturing process to make it commercial-ready are now coming to fruition,” Dr Collier says. “We're at the point where Photonz can now sit down and speak to potential partners about commercial-scale manufacturing and supply into an already established market.

“The market for EPA as a treatment is there – what we're offering is a more efficient, sustainable, reliable, scalable and high-purity source of this important omega-3 fatty acid.”

Dr Collier said interest had been expressed for Photonz's EPA products at varying levels of purity. The Photonz manufacturing process – which is on-track to reach industrial-scale capability around the end of this year - can produce EPA at purity levels varying from a 20% - 25% basic form, to a 97% EPA product suited to pharmaceutical uses.

Dr Collier said talks with potential partners would also take place later this month at the Health Ingredients Europe conference (13 – 15 November) in Frankfurt, Germany.

This conference would also present an opportunity to highlight the environmental sustainability of Photonz's EPA products compared to fish oil-sourced EPA, as well as its potential as an additive in vegetarian foods.

“This will be the only non GM vegetarian source of purified EPA, and a source of EPA that is not a bi-product of the fishing industry,” Dr Collier said.  “There is a broader discussion that global fish stocks are in decline and the more the market for omega-3 fatty acids - including EPA - grows so it will exert even more pressure.”

Dr Collier said Photonz's EPA may allow food companies to add to a new marketable claim to their products - noting they deliver the benefits of fish oil while being sustainable and relieving pressure on fish stocks.

About Photonz: Founded in New Zealand in 2002, Photonz Corporation produces the omega-3 fatty acid eicosapentaenoic acid (EPA) which is a critical ingredient in novel therapeutics for the cardiovascular disease market. Photonz has proprietary control over a unique fermentation process involving an EPA-rich strain of marine microalgae. This has been shown to produce EPA in a range of purities up to 97% and to be suited to pharmaceutical applications. Photonz is approaching a commercial-ready phase with facilities in the UK and France involved in late-stage up-scaling of an already proven manufacturing process. EPA, which has a range of food-based and therapeutic applications, is otherwise derived from fish oil.


For media inquiries please contact:

Fred Russo, Botica Butler Raudon Partners, +64 21 403 509 or
Richard Justice, Photonz, +64 21 223 4741 or